Phreesia, Inc. (NYSE:PHR) COO Sells $162,366.36 in Stock

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 7,178 shares of Phreesia stock in a transaction on Monday, April 8th. The shares were sold at an average price of $22.62, for a total transaction of $162,366.36. Following the sale, the chief operating officer now directly owns 733,602 shares of the company’s stock, valued at approximately $16,594,077.24. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Evan Roberts also recently made the following trade(s):

• On Thursday, March 21st, Evan Roberts sold 25,962 shares of Phreesia stock. The shares were sold at an average price of $23.52, for a total transaction of $610,626.24.
• On Tuesday, January 16th, Evan Roberts sold 2,247 shares of Phreesia stock. The shares were sold at an average price of $24.55, for a total transaction of $55,163.85.

Phreesia Stock Performance

NYSE:PHR opened at $23.80 on Friday. The firm’s 50-day moving average is $24.76 and its 200-day moving average is $21.09. Phreesia, Inc. has a 52-week low of $12.05 and a 52-week high of $34.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.78 and a current ratio of 1.78. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -9.44 and a beta of 0.92.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. The company had revenue of $95.00 million for the quarter, compared to the consensus estimate of $93.52 million. During the same quarter in the previous year, the firm posted ($0.72) EPS. The business’s revenue was up 24.0% compared to the same quarter last year. Equities research analysts anticipate that Phreesia, Inc. will post -1.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PHR. DA Davidson restated a “neutral” rating and set a $32.00 price target on shares of Phreesia in a report on Friday, March 15th. JMP Securities raised their price target on shares of Phreesia from $28.00 to $30.00 and gave the company a “market outperform” rating in a report on Thursday, March 21st. Barclays initiated coverage on shares of Phreesia in a report on Wednesday, January 3rd. They set an “overweight” rating and a $29.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Friday, March 15th. Finally, Raymond James reiterated an “outperform” rating and issued a $30.00 target price (up previously from $25.00) on shares of Phreesia in a report on Friday, March 15th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Phreesia presently has a consensus rating of “Moderate Buy” and an average target price of $31.62.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. CI Investments Inc. increased its stake in Phreesia by 6.6% in the third quarter. CI Investments Inc. now owns 477,265 shares of the company’s stock valued at $8,915,000 after acquiring an additional 29,500 shares during the period. Schroder Investment Management Group bought a new stake in Phreesia in the third quarter valued at about $6,514,000. TimesSquare Capital Management LLC increased its stake in Phreesia by 7.8% in the third quarter. TimesSquare Capital Management LLC now owns 774,079 shares of the company’s stock valued at $14,460,000 after acquiring an additional 55,793 shares during the period. Lazard Asset Management LLC increased its stake in Phreesia by 58.6% in the third quarter. Lazard Asset Management LLC now owns 424,047 shares of the company’s stock valued at $7,921,000 after acquiring an additional 156,711 shares during the period. Finally, Trust Point Inc. bought a new stake in Phreesia in the fourth quarter valued at about $239,000. Institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.